MedTrace Logo

Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders

NCT00006056 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2005-06-24

No results posted yet for this study

Summary

OBJECTIVES: I. Determine the efficacy of unrelated donor hematopoietic stem cell transplantation in the treatment of patients with life threatening hemophagocytic disorders.

II. Determine the rate of disease free survival, incidence of graft failure, and incidence of graft versus host disease in these patients after undergoing this treatment regimen.

Conditions

  • Chediak-Higashi Syndrome
  • Graft Versus Host Disease
  • X-Linked Lymphoproliferative Syndrome
  • Familial Erythrophagocytic Lymphohistiocytosis
  • Hemophagocytic Lymphohistiocytosis
  • Virus-Associated Hemophagocytic Syndrome

Interventions

DRUG

anti-thymocyte globulin

DRUG

busulfan

DRUG

cyclophosphamide

DRUG

cyclosporine

DRUG

etoposide

DRUG

filgrastim

DRUG

methotrexate

PROCEDURE

allogeneic hematopoietic stem cell transplantation

Sponsors & Collaborators

  • Fairview University Medical Center

    lead OTHER

Principal Investigators

  • K. Scott Baker · Fairview University Medical Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
0 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006056 on ClinicalTrials.gov